Long-term efficacy, safety, and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT

被引：0
|
作者：
Mease, Philip J.
Gladman, Dafna
Ritchlin, Christopher
Sasso, Eric
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
104
引用
收藏
页码：1820 / 1820
页数：1
相关论文
共 50 条
  • [21] Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
    Kavanaugh, AF
    Ritchlin, CT
    Malaise, MG
    Wordsworth, P
    Birbara, CA
    Weinberg, MA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 325 - 325
  • [22] Adalimumab is effective against skin and joint disease in psoriatic arthritis patients: 48-week results of ADEPT
    Mease, P. J.
    Gladman, D. D.
    Ritchlin, C. T.
    Ruderman, E. M.
    Choy, E. H. S.
    Steinfield, S. D.
    Sharp, J. T.
    Ory, P.
    Wang, H.
    Sasso, E.
    RHEUMATOLOGY, 2006, 45 : I68 - I69
  • [23] LONG-TERM EFFICACY OF ADALIMUMAB AND ETANERCEPT IN PSORIATIC ARTHRITIS PATIENTS: PROLONGED INTERVALS BETWEEN INJECTIONS
    Lorenzin, M.
    Ramonda, R.
    Modesti, V.
    Ortolan, A.
    Frallonardo, P.
    Punzi, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 948 - 948
  • [24] Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis
    Strand, Vibeke
    LANCET RHEUMATOLOGY, 2021, 3 (04): : E239 - E240
  • [25] Adalimumab is efficacious in treating joint disease in early and established psoriatic arthritis: Subanalysis of ADEPT
    Choy, E.
    Gladman, D. D.
    Sasso, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 211 - 211
  • [26] Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim A.
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Stakias, Vassilis
    Iyile, Thomas
    Carter, Kyle
    Soliman, Ahmed
    Drogaris, Leonidas
    Chen, Michael
    Padilla, Byron
    Kivitz, Alan
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2823 - 2826
  • [27] IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING ADALIMUMAB, IMPROVEMENT IN PSORIASIS IS ASSOCIATED WITH LONG-TERM INHIBITION OF RADIOGRAPHIC PROGRESSION
    Choy, E.
    Gladman, D.
    Mease, P. J.
    Ritchlin, C.
    Olds, M.
    Wong, R. L.
    Wang, S.
    Medich, J.
    RHEUMATOLOGY, 2009, 48 : I56 - I57
  • [28] Long-term safety and efficacy of adalimumab therapy in patients with juvenile rheumatoid arthritis (JRA) - Results from over 2 years of treatment
    Ruperto, N.
    Lovell, D. J.
    Goodman, S.
    Reiff, A.
    Nemcova, D.
    Prieur, A. M.
    Joos, R.
    McIlraith, M.
    Martini, Alberto
    Giannini, E.
    RHEUMATOLOGY, 2008, 47 : II2 - II3
  • [29] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    Peterfy, C.
    Durez, P.
    Tanaka, Y.
    Swierkot, J.
    Khan, N.
    Bu, X.
    Li, Y.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 251 - 252
  • [30] Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1708 - 1710
12345